论文信息 - Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells

Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells

To the Editor: We read with interest the article by Bogos et al. ([1][1]), which showed that circulating lymphatic/vascular endothelial progenitor cells (LVEPC) are significantly increased in small cell lung cancer (SCLC) patients and correlate with clinical behavior. We wish to comment on several

B. Besse | Y. Loriot | J. Rössler | F. Farace | Mélissa Taylor

[1] G. Lang,et al. High VEGFR-3–positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[2] F Dignat-George,et al. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry , 2006, Cytometry. Part B, Clinical cytometry.

[3] S. Rafii,et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. , 2003, Blood.

[4] S. Rafii,et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.